Gilead Highlights Progress In Research Across HIV Prevention, Treatment And Cure Programs At AIDS 2024
Gilead Highlights Progress In Research Across HIV Prevention, Treatment And Cure Programs At AIDS 2024
- Late-Breaking Full Results from HIV Prevention Research of Twice-Yearly Injectable Lenacapavir -
- 將兩年一次注射劑Lenacapavir用於艾滋病預防的後期結果
- Progress and Person-Centered Approaches Across HIV Treatment, Cure Research and Development Programs -
- 在治療、治癒研究和開發計劃全面推進和以人爲中心的方法方面取得進展
- Key Initiatives Demonstrate Commitment to Collaboration to Help End the HIV Epidemic Worldwide -
- 重要舉措體現了合作致力於幫助全球終結艾滋病流行的承諾
Gilead Sciences, Inc. (NASDAQ:GILD) today announced its program for the upcoming 25th International AIDS Conference (AIDS 2024), taking place in Munich, Germany, and virtually, from July 22-26. As the leading innovator in HIV, Gilead will share new data from its research and development programs and Gilead-supported collaborations that unite leading scientific innovation and partnership aimed at ending the HIV epidemic.
吉利德科學公司（納斯達克：GILD）今天宣佈了其即將到來的第25屆國際艾滋病會議（AIDS 2024）計劃，該會議將於7月22日至26日在德國慕尼黑和虛擬線上舉行。作爲艾滋病領先創新者，吉利德將分享自己的研究開發計劃和吉利德支持的合作方面的新數據，這些合作團結了領先的科學創新和夥伴關係，旨在終結艾滋病疫情。